On Friday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Spectrum Pharmaceuticals, (NASDAQ:SPPI), Chanticleer Holdings (NASDAQ:HOTR), Crestwood Equity Partners LP (NYSE:CEQP), Geron (NASDAQ:GERN)
On Mar 23, 2015 Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) divulged financial results for the three-month period and year ended December 31, 2014.
Total revenues were $51.9 million and product sales were $51.7 million in the fourth quarter of 2014. Total revenue increased 25% from $41.5 million in the fourth quarter of 2013, while product sales increased 28% from $40.5 million in the 4th Q of 2013.
Product sales in the fourth quarter included: FUSILEV® (levoleucovorin) net sales of $30 million, FOLOTYN® (pralatrexate injection) net sales of $12.2 million, ZEVALIN® (ibritumomab tiuxetan) net sales of $5 million, MARQIBO® (vinCRIStine sulfate LIPOSOME injection) net sales of $1.6 million and BELEODAQ® (belinostat) for Injection nets sales of $2.9 million.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) decreased -3.74%, and closed at $6.17. The company holds the market capitalization of $412.60M. For the last twelve months, the stock was able to keep return on equity at -17.50%, while return on assets at -9.40%, in response to its return on investment at -9.60%. Its 20-day moving average decreased -2.09%, below 50-day moving average of -8.12%, below 200-day moving average of -16.96% from the latest market price of $6.17. The mean recommendation of analysts for this stock is 2.50. (Where 1=Buy, 5=Sale).
Spectrum Pharmaceuticals, Inc. (SPPI) a biotechnology company develops and commercializes oncology and hematology drug products. The company markets five drug products, including FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; and BELEODAQ injection for patients with relapsed or refractory PTCL.
On March 20, 2015 Chanticleer Holdings Inc (NASDAQ:HOTR) owner and operator of multiple restaurant brands internationally and domestically, uncovered that it closed on the acquisition of BGR: The Burger Joint (“BGR”), a better burger concept well-known in the Maryland/Washington, D.C./Virginia area. BGR closed out 2014 with $15+ million in system wide retail sales, $10+ million in company revenue, nine corporate owned locations and nine franchises. It added two additional locations in Q1 2015 including its first international franchise location in Kuwait and has over eighty franchise locations under development agreement almost equally split between domestic and international markets. BGR was voted #7 Burger Chain in USA by The Daily Meal & MSN.com, #1 Burger Restaurant by the Washingtonian and #1 Burger Patty by the Washington Post.
Chanticleer Holdings Inc (NASDAQ:HOTR) declined -1.15%, and closed at $2.59. The company has the market capitalization of $20.64 million. The beta value of the stock is 6.33. On the other hand the stock’s volatility for the week is 17.60%, and for the month is 11.89%. The stock’s price to book ratio is $1.15, however price to sale ratio is $0.81. Analyst’s mean recommendation regarding this stock is 2.00. (Where 1=Buy, 5=Sale).
Chanticleer Holdings Inc (HOTR) owns and operates Hooters franchises in the United States and internationally. The company’s Hooters restaurants are casual beach-themed establishments with sports on television, jukebox music, and the Hooters Girls facilities.
Formerly on February 24, 2015 Crestwood Equity Partners LP (NYSE:CEQP) uncovered its financial results for the three and twelve months ended December 31, 2014 and provided its 2015 outlook. Crestwood Equity owns the general partner of Crestwood Midstream Partners LP (CMLP) (“Crestwood Midstream” or “CMLP”).
Crestwood Equity Partners LP (NYSE:CEQP) fell -3.64%, and closed at $5.83. The stock has the beta value of 0.76, and its volatility for the week is 4.70%, while for the month it is 4.55%. The company has the market capitalization of $1.09 billion. The company holds the book value per share of 4.26, whereas cash per share is 0.05. Price to book ratio remained 1.37, while price to sale ratio is 0.28. Analysts mean recommendation for the stock is said to be 2.40 (where 1=Buy, 5=sale).
Crestwood Equity Partners LP (CEQP) offers midstream solutions to customers in the crude oil, natural gas liquids (NGLs), and natural gas sectors of the energy industry in the United States. It operates through three segments: Gathering and Processing; Storage and Transportation; and NGL and Crude Services.
Formerly on March 3, 2015 Geron Corporation (NASDAQ:GERN) unveiled financial results for the fourth quarter and year ended December 31, 2014 and recent events.
Net loss for the fourth quarter of 2014 was $8.9 million, or $0.06 per share, compared to $9.3 million, or $0.07 per share, for the comparable 2013 period. Revenues for the fourth quarter of 2014 were $178,000 compared to $225,000 for the comparable 2013 period. The company ended 2014 with $170.6 million in cash and investments, which included receipt of an upfront payment of $35.0 million for the license rights granted by the company to Janssen Biotech, Inc. (“Janssen”) under the exclusive collaboration and license agreement (the “Collaboration Agreement”) entered into between the parties in November 2014, which has been recorded as deferred revenue as of December 31, 2014.
Geron Corporation (NASDAQ:GERN)’s shares picked down -3.63%, and closed at $3.98. The stock volatility for the week is 5.96%, while for the month remained 8.10%. The company holds consensus target price of $5.50.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.23 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 23.30% and Annual EPS growth for the past 5 years is considered as 22.10%.
The mean recommendation of analysts for this stock is 2.50. (Where 1=Buy, 5=Sale).
Geron Corporation (GERN) a clinical stage biopharmaceutical company, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
